Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose Limiting normal tissues and radiation dose-escalation:: A planning study

被引:111
作者
De Ruysscher, D
Wanders, S
Minken, A
Lumens, A
Schiffelers, J
Stultiens, C
Halders, S
Boersma, L
van Baardwijk, A
Verschueren, T
Hochstenbag, M
Snoep, G
Wouters, B
Nijsten, S
Bentzen, SM
van Kroonenburgh, M
Öllers, M
Lambin, P
机构
[1] UH Maastricht, GROW, MAASTRO, Dept Radiat Oncol, NL-6419 PC Maastricht, Netherlands
[2] MAASTRO Clin, Maastricht, Netherlands
[3] Univ Hosp Maastricht, Dept Nucl Med, Maastricht, Netherlands
[4] Univ Hosp Maastricht, Dept Lung Dis, Maastricht, Netherlands
[5] Univ Hosp Maastricht, Dept Radiol, Maastricht, Netherlands
[6] Univ Wisconsin, Sch Med, Madison, WI USA
关键词
PET-CT; NSCLC; radiotherapy; planning; dose-escalation; toxicity;
D O I
10.1016/j.radonc.2005.06.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: To investigate the effect of radiotherapy planning with a dedicated combined PET-CT simulator of patients with locally advanced non-small cell lung cancer. Patients and methods: Twenty-one patients underwent a pre-treatment simulation on a dedicated hybrid PET-CT-dsimulator. For each patient, two 3D conformal treatment plans were made: one with a CT based PTV and one with a PET-CT based PTV, both to deliver 60 Gy in 30 fractions. The maximum tolerable prescribed radiation dose for CT versus PET-CT PTV was calculated based on constraints for the lung, the oesophagus, and the spinal cord, and the Tumour Control Probability (TCP) was estimated. Results: For the same toxicity levels of the lung, oesophagus and spinal cord, the dose could be increased from 55.2 +/- 2.0 Gy with CT planning to 68.9 +/- 3.3 Gy with the use of PET-CT (P=0.002), with corresponding TCP's of 6.3 +/- 11.5% for CT and 24.0 +/- 5.6% for PET-CT planning (P=0.01). Conclusions: The use of a combined dedicated PET-CT-simulator reduced radiation exposure of the oesophagus and the lung, and thus allowed significant radiation dose escalation whilst respecting all relevant normal tissue constraints. (C) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:5 / 10
页数:6
相关论文
共 20 条
[1]   Non-small cell lung cancer: Dual-modality PET/CT in preoperative staging [J].
Antoch, G ;
Stattaus, J ;
Nemat, AT ;
Marnitz, S ;
Beyer, T ;
Kuehl, H ;
Bockisch, A ;
Debatin, JF ;
Freudenberg, LS .
RADIOLOGY, 2003, 229 (02) :526-533
[2]  
Bentzen SM, 1997, INT J RADIAT BIOL, V71, P531, DOI 10.1080/095530097143860
[3]   Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer [J].
Bradley, J ;
Thorstad, WL ;
Mutic, S ;
Miller, TR ;
Dehdashti, F ;
Siegel, BA ;
Bosch, W ;
Bertrand, RJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (01) :78-86
[4]   Can pet provide the 3D extent of tumor motion for individualized internal target volumes? A phantom study of the limitations of CY and the promise of PET [J].
Caldwell, CB ;
Mah, K ;
Skinner, M ;
Danjoux, CE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 55 (05) :1381-1393
[5]   Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT):: A feasibility study [J].
Ciernik, IF ;
Dizendorf, E ;
Baumert, BG ;
Reiner, B ;
Burger, C ;
Davis, JB ;
Lütolf, UM ;
Steinert, HC ;
Von Schulthess, GK .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (03) :853-863
[6]  
CURRAN W, 2003, P ASCO, V9410, P2499
[7]  
DERUYSSCHER D, 2005, IN PRESS INT J RAD O
[8]   Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer [J].
Furuse, K ;
Fukuoka, M ;
Kawahara, M ;
Nishikawa, H ;
Takada, Y ;
Kudoh, S ;
Katagami, N ;
Ariyoshi, Y .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2692-2699
[9]   Respiration-induced attenuation artifact at PET/CT: Technical considerations [J].
Goerres, GW ;
Burger, C ;
Kamel, E ;
Seifert, B ;
Kaim, AH ;
Buck, A ;
Buehler, TC ;
von Schulthess, GK .
RADIOLOGY, 2003, 226 (03) :906-910
[10]   Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) [J].
Graham, MV ;
Purdy, JA ;
Emami, B ;
Harms, W ;
Bosch, W ;
Lockett, MA ;
Perez, CA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 45 (02) :323-329